Abstract
Insulin Dependent Diabetes Mellitus (IDDM type I) is the result of autoimmune destruction of insulin producing pancreatic β-cells by the cellular immune system, specifically, autoreactive T cells. Disease progression is evident by multiple autoantibodies responding to self-antigens in a cascade mechanism, wherein the first self-antigen induces the activation of the immune system, leading to the destruction of β-cells and consequently, exposure of other antigens. Glutamic Acid Decarboxylase (GAD) is recognized in the literature as a primary autoantigen involved in the cascade. We questioned the immunological involvement of this autoantigen in the overall progression of the disease, specifically if antigen recognition by the cellular immune system (T cells) is necessary for organ specific autoimmunity and cellular toxicity. We tested this hypothesis by isolating, purifying and injecting monoclonal antibodies against GAD (anti-GAD Ab; 0.1 mg or 0.3 mg) into non-obese diabetic (NOD) mice on a weekly basis. We suggest that the anti-GAD Ab will bind to the GAD antigen, or perhaps bind to the epitope presented in association with APC-MHC and prevent T cell recognition, thereby delaying disease onset. Our results demonstrate a delay in the onset of diabetes and a decrease in the severity of insulitis in our test animals, when compared to controls. The mechanism of action of the anti-GAD Ab may be associated with a passive protection mechanism, as evidenced by the fact that splenocytes transferred from anti-GAD Ab treated mice did not prevent or delay diabetes in syngeneic irradiated NOD mice. The mechanism of diabetes prevention by administration of anti-GAD antibody could be associated with an interference in recognition of GAD by T cells, and continuing research will be perform to investigate this hypothesis.
Article PDF
Similar content being viewed by others
REFERENCES
M. Nagata and J.-W. Yoon. Studies on autoimmunity for T cell-mediated β-cell destruction. Distinct difference in β-cell destruction between CD4+ and CD8+ T cell clones derived from lymphocytes infiltrating the islets of NOD mice. Diabetes 41:998–1008 (1992).
D. Daniel, R. G Gill, N. Schoot, and D. Wegmann. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25:1056–1062 (1995).
R. S. Liblau, S. M. Singer, and H. O. McDevitt. Th1 and Th2 CD4+ T cells in the pathogenesis of organ specific autoimmune diseases. Immunology Today 16:34–38 (1995).
A. R Hayward and M. Shreiber. Neonatal injection of CD3 antibody into non-obese diabetic mice reduces the incidence of insulitis and diabetes. J. Immunol. 143(3):1555–1559 (1989).
B. Hehmke, B. Kuttler, F. Laube, E. Gens, D. Michaelis, H. J. Hahn, H. Schulze-Koops, and F. Emmrich. Anti-CD4 monoclonal antibody immune intervention in patients with newly diagnosed type I (insulin-dependent) diabetes mellitus. Diab. Nutr. Metab. 7:273–280 (1994).
N. Fabien, I. Bergerot, J. Orgiazzi, and C. Thivolet. Anti-selectin and anti-ICAM 1, mAbs delay the onset of diabetes in NOD mice. Diabetes 44:(Suppl 1): 137A (1995).
A. Rabinovitch. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM therapeutic intervention by immunosti-mulation. Diabetes 43:613–621 (1994).
M. Rocken, M. Racke, and E. M. Shevach. IL-4 induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 17,5:225–231 (1996).
T. Kobayashi, K. Nakanishi, T. Murase, and K. Kosaka. Subtype of islet cell antibodies and slowly progressive beta-cell failure. Diabetologia 36:92–96 (1993).
J. Timsit, S. Caillat-Zucman, H. Blondel, P. Chedin, J. F. Bach, and C. Boitard. Islet cell antibody heterogeneity among type I (insulin dependent) diabetic patients. Diabetologia 35:792–795 (1992).
A. E. Karlsen, W. A. Hagopian, J. S. Petersen, E. Boel, T. Dyrberg, C. E. Grubin, B. K. Michelsen, O. D. Madsen, and A. Lernmark. Recombinant glutamic acid decarboxylase (representing the single isoform expressed in the human islets) detects IDDM-associated 64,000-Mr autoantibodies. Diabetes 41:1355–1359 (1992).
J. Seissler, J. Amann, L. Mauch, H. Haubruck, S. Wolfahrt, S. Bieg, W. Richter, R. Holl, E. Heinze, W. Northemann, and W. A. Scherbaum. Prevalence of autoantibodies to the 65-and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J. Clin. Invest. 92:1394–1399 (1993).
S. Bieg, E. M. Bailyes, N. Yassin, J. Amann, L. Herberg, A. M. McGregor, W. A. Scherbaum, and J. P. Banga. A multiplicity of protein antigens in subcellular fraction of rat insulinoma tissue are able to stimulate T cells obtained from non-obese diabetic mice. Diabetologia, 36:385–390 (1993).
E. Bjork, O. Kampe, J. Grawe, A. Hallberg, I. Norheim, and F. A. Karlsson. Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. Autoimmunity 16:181–188 (1993).
R. Tisch, X. D. Yang, S. Singer, R. S. Liblau, L. Fugger, and H. O. McDevitt. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366:72–75 (1993).
D. L. Kaufman, M. Clare-Salzler, J. Tian, T. Forsthuber, G. S. Ting, P. Robinson, M. A. Atkinson, E. E. Sercarz, A. J. Tobin, and P. J. Lehmann. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 344:69–72 (1993).
J. M. Pleau, F. Fernandez-Saravia, A. Esling, F. Homo-Delarche, and M. Dardenne. Prevention of autoimmune diabetes in non-obese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD65). Clin. Immunol. Immunopath. 751:90–95 (1995).
J. Tian, M. Atkinson, M. Clare-Salzler, A. Herschenfeld, T. Forsthuber, P. Lehmann, and D. Kaufman. Nasal administration of glutamate decarboxylase peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183:1561–1567 (1996).
P. Sai, S. Rivereau, C. Granier, T. Haertle, and L. Martignat. Immunization of non-obese diabetes (NOD) mice with glutamic acid decarboxylase-derived peptide 524–543 reduces cyclophosphamide accelerated diabetes. Clin. Exp. Immunol. 105:330–337 (1996).
J. F. Elliott, H.-Y. Quin, S. Bhatti, D. K. Smith, R. Kumari, T. Dillon, J. Lauzon, and B. Singh. Immunization with a larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes 43:1494–1499 (1994).
B. Ziegler, E. Lucke, B. Helmke, M. Schlosser, S. Witt, W. Besh, and M. Ziegler. Monoclonal antibody-mediated cytotoxicity against rat beta cells detected in vitro does not cause beta-cell destruction in vivo. Diabetologia 35:608–613 (1992).
A. Bendelac, C. Boitard, and J. F. Bach. Adoptive T cell transfer of autoimmune non obese diabetes does not require recruitment of host B lymphocytes. J. Immunol. 14:2625–2629 (1988).
L. C. Harrison, M. C. Honeyman, H. J. DeAizpurua, R. S. Schmidli, P. G. Colman, B. D. Jait, and D. S. Cram. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341:1365–69 (1993).
H. Noorchashm, N. Noorchashm, J. Kern, S. Y. Rostami, C. F. Barker, and A. Naji. B-cells are required for initiation of insulitis and sialitis in non obese diabetic mice. Diabetes 46:941–946 (1997).
D. Gottlieb, Y. C. Chang, and J. E. Schwab. Monoclonal antibodies to glutamic acid decarboxylase. Proc. Natl. Acad. Sci. USA 83:8808–8812 (1986).
J. L. Diaz, J. Ways, and P. Hammonds. T-lymphocyte lines specific for glutamic acid decarboxylase (GAD) the 64 K beta-cell antigen of IDDM. Diabetes 41:118–121 (1992).
I. Hara, Y. Takechi, and A. N. Houghton. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the Brown locus protein. J. Exp. Med. 182:1609–1614 (1995).
R. B. Pedley, J. A. Boden, R. Boden, R. H. J. Begent, A. Turner, A. M. R. Haines, and D. J. King. The potential for enhanced tumor localization by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer 70:1126–1130 (1994).
B. Charlton and T. E. Mandel. Progression from insulitis to beta cell destruction in NOD mouse requires L3T4+ T-lymphocytes. Diabetes 37:1108–1113 (1988).
D. Ulaeto, P. E. Lacy, D. M. Kipnis, O. Kanagawa, and E. R. Unanue. A T-cell dormant state in the autoimmune process of non-obese diabetic mice treated with complete Freund's Adjuvant. Proc. Natl. Acad. Sci. USA 89:3927–3931 (1992).
I. Bergerot, N. Fabien, V. Maguer, and C. Thivolet. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J. Autoimmun. 7:655–663 (1994).
I. Bergerot, N. Fabien, A. Mayer, and C. Thivolet. Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Annal. NY Acad. Sci. 778:362–367 (1996).
A. Lanzavecchia. How can cryptic epitopes trigger autoimmunity?. J. Exp. Med. 181:1635–1642 (1995).
P. D. Simitsek, D. G. Cambpell, A. Lanzavecchia, N. Fairweather, and C. Watts. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181:1957–1963 (1995).
C. Watts and A. Lanzavecchia. Suppressive effect of antibody on processing of T cell epitopes. J. Exp. Med. 178:1459–1463 (1993).
A. G. Baxter and A. Cooke. The pathogenesis of autoimmune diabetes in NOD mice. Diabetes 42:1574–1578 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Menard, V., Jacobs, H., Jun, HS. et al. Anti-GAD Monoclonal Antibody Delays the Onset of Diabetes Mellitus in NOD Mice. Pharm Res 16, 1059–1066 (1999). https://doi.org/10.1023/A:1018939900961
Issue Date:
DOI: https://doi.org/10.1023/A:1018939900961